PGEN

Precigen Inc

5.64

+0.39+7.43%

After Hours: 5.60 -0.04 -0.71%19:54 07/02 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE5.33/5.25

TODAY RANGE5.26-5.66

VOL4.77M

MARKET CAP2.01B

52 WEEK RANGE1.395-6.04

AVG VOL (3M)4.37M

% TURNOVER1.34%

TURNOVER--

P/E (TTM)-4.5565

% RANGE7.59%

EPS(TTM)-1.2378

P/E(FORWARD)-112.8000

P/B99.12

BVPS0.0569

DIVIDEND--

P/S205.84

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP1.74B

SHARES OUTSTANDING356.51M

NEXT EARNINGS08/10-08/14

FREE FLOAT307.85M

LOT SIZE1

EX-DATE01/19/2017

News

Press Releases

Financial Reports

Profile

PUBT·3d ago
Precigen CEO Helen Sabzevari disposes of 346,836 common shares worth $2,042,858.04
Seeking Alpha·06/26 19:37
Precigen: Entering The Oncology 'Sweet Spot'
TipRanks·06/24 20:31
Precigen Shareholders Expand Incentive Plan, Reaffirm Governance
PUBT·06/24 20:08
Precigen shareholders approve 7 million-share increase to 2023 incentive plan at annual meeting
PUBT·06/15 10:40
Precigen reports PAPZIMEOS trial data show 83% complete responses sustained at least 36 months in RRP
NASDAQ·06/12 03:54
Top Biotech Gainers: VRXA Begins A New Chapter, ADIL Opens Wallet, PGEN, PCSA On Watch...
PR Newswire·06/11 12:00
Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices
TipRanks·06/02 11:10
Analysts Offer Insights on Healthcare Companies: ImmunityBio (IBRX), Abivax SA Sponsored ADR (ABVX) and Precigen (PGEN)
TipRanks·06/02 02:02
Massive Insider Stock Dump Rocks Precigen Leadership Ranks
TipRanks·05/31 21:35
Precigen presents long-term follow-up data from study of Papzimeos
PUBT·05/30 18:30
Precigen says PAPZIMEOS trial shows 83% of complete responders remain disease-free at 36 months+
PR Newswire·05/30 18:30
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
Dow Jones·05/28 11:02
Precigen Price Target Raised to $14.00/Share From $11.00 by HC Wainwright & Co.
Dow Jones·05/28 11:02
Precigen Is Maintained at Buy by HC Wainwright & Co.
TipRanks·05/28 10:13
Precigen price target raised to $14 from $11 at H.C. Wainwright

Same Industry

Name/Symbol

Change%

Price

PGEN

MCK

Biogen Inc

BIIB

+0.28%

216.63

Amgen Inc

AMGN

+1.56%

358.33

Shire

SHPG

0.00%

179.20

Bristol-Myers Squibb Company Celegne Contingent Value Rights

CELG-RT

-1.08%

0.1187

LLY

CELG

TXMD

Johnson & Johnson

JNJ

-1.76%

253.97

Abbvie Inc

ABBV

-0.66%

252.63

ZTS

Gilead Sciences Inc

GILD

+3.68%

130.61

Novo-Nordisk A/S

NVO

+3.68%

50.56

Bristol-Myers Squibb Co

BMY

+3.35%

57.68

Alexion Pharms

ALXN

+1.70%

182.50

PFE

Sanofi FR

SNY

+2.75%

42.95

GCVRZ

Novartis

NVS

-1.24%

154.78

Dr Reddys Labs

RDY

-3.45%

13.99

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.